Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.82M | $10.2M | $16.6M | $28.2M | $27.7M | $48.5M | $44.5M | $52.3M | $48.1M | $52.8M |
| Revenue growth | — | 16.0% | 62.3% | 70.0% | -1.9% | 75.1% | -8.3% | 17.6% | -8.1% | 9.9% |
| Gross profit | $5.12M | $6.96M | $10.8M | $19.1M | $17.5M | $33.6M | $29.1M | $33.8M | $29.4M | $33.0M |
| Gross margin | 58.0% | 68.0% | 65.2% | 67.6% | 63.2% | 69.3% | 65.4% | 64.5% | 61.0% | 62.5% |
| Operating income | -$11.4M | -$13.9M | -$14.3M | -$20.9M | -$20.1M | -$14.4M | -$23.6M | -$17.3M | -$18.8M | -$6.45M |
| Operating margin | -129.2% | -135.7% | -86.0% | -73.9% | -72.5% | -29.8% | -52.9% | -33.0% | -39.2% | -12.2% |
| Net income | -$11.6M | -$5.06M | $62.7M | -$19.7M | -$11.9M | -$15.2M | -$23.2M | -$18.7M | -$23.5M | -$11.2M |
| Net margin | -131.0% | -49.5% | 377.7% | -69.8% | -42.9% | -31.3% | -52.1% | -35.7% | -48.8% | -21.2% |
| EPS (diluted) | -$0.15 | -$0.17 | $1.83 | -$0.58 | -$0.35 | -$0.44 | -$0.67 | -$0.54 | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.84M | -$3.70M | -$20.9M | -$18.5M | -$16.1M | -$10.4M | -$20.3M | -$5.25M | -$18.0M | -$8.00M |
| Capital expenditures | $286K | $624K | $363K | $1.30M | $581K | $723K | $1.01M | $533K | $722K | $1.11M |
| Free cash flow | -$3.12M | -$4.33M | -$21.2M | -$19.8M | -$16.6M | -$11.2M | -$21.3M | -$5.78M | -$18.8M | -$9.12M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $14.5M | $9.95M | $40.7M | $58.8M | $41.9M | $30.9M | $10.2M | $43.7M | $31.7M | $31.7M |
| Total assets | $35.1M | $31.0M | $113M | $84.7M | $74.1M | $68.7M | $51.8M | $79.2M | $64.8M | $66.8M |
| Total liabilities | $8.89M | $8.96M | $22.6M | $13.5M | $10.3M | $14.7M | $14.0M | $52.3M | $50.5M | $52.0M |
| Long-term debt | $2.69M | $2.46M | $0.00 | — | — | — | $0.00 | $33.2M | $33.9M | $34.8M |
| Shareholders' equity | $26.2M | $22.0M | $90.6M | $71.3M | $63.7M | $53.7M | $37.6M | $26.7M | $14.2M | $14.5M |
| Retained earnings | -$23.4M | -$28.5M | $38.8M | $14.5M | $2.62M | -$12.6M | -$35.7M | -$54.4M | -$77.9M | -$89.1M |
| Shares (wtd avg diluted) | 27.4M | 31.4M | 33.2M | 34.1M | 34.2M | 34.3M | 34.5M | 34.6M | 35.5M | 41.1M |
Every figure is extracted from Apyx Medical Corp’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.